FO
FOLD

FT Options’s Amicus Therapeutics FOLD Stock Holding History

FT Options’s Portfolio FOLD Stock Details FOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		$633K Buy
115,300
+31,000
+37% +$410K 0.95% 36
2017
Q2 		$262K Buy
84,300
+2,500
+3% +$20.1K 0.45% 48
2017
Q1 		$123K Buy
81,800
+54,600
+201% +$345K 0.16% 104
2016
Q4 		$4K Sell
27,200
-3,200
-11% -$22.1K ﹤0.01% 219
2016
Q3 		$50K Buy
+30,400
New +$205K 0.04% 211
2016
Q2 		– Sell
-20,400
Closed -$34K – 369
2016
Q1 		$34K Buy
+20,400
New +$144K 0.04% 189

Other funds holding FOLD

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $145B AUM 34.61% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return

FT Options's FOLD Position: Q1 2017 in Review

FT Options sold out of Amicus Therapeutics (FOLD) in Q1 2017, closing a stake of 8,792 shares — an estimated $55.6K sold.

FT Options first reported a position in FOLD in Q4 2016 and held it in 1 quarter. The position peaked at $44K in Q4 2016. 134 funds tracked by Wall St. Rank hold FOLD as of Q1 2017.

  • FT Options reported no remaining Amicus Therapeutics position as of Q1 2017 after selling out during the quarter.
  • FT Options sold 8,792 Amicus Therapeutics shares in Q1 2017, an estimated $55.6K.
  • FT Options first reported a position in Amicus Therapeutics in Q4 2016 and held it in 1 quarter.
  • FT Options's Amicus Therapeutics position peaked at $44K in Q4 2016.
  • 134 funds tracked by Wall St. Rank held Amicus Therapeutics as of Q1 2017.

Based on FT Options's 13F filing for Q1 2017, filed 12 May 2017.